Investigation on the Current Situation of Adverse Drug Reaction Monitoring in Agricultural Reclamation of Heilongjiang Province

Chinese Journal of Pharmacovigilance ›› 2014, Vol. 11 ›› Issue (10): 621-623.

Previous Articles Next Articles

Investigation on the Current Situation of Adverse Drug Reaction Monitoring in Agricultural Reclamation of Heilongjiang Province

CHEN Hao-qun¹, XIA Hong-bo^{1, *}, ZHAO Shi-dan², HU Chen-xia¹, JIANG Zhi-yuan¹

1Heilongjiang Agriculture and Reclamation Bureau Adverse Drug Reaction Monitoring Center, Heilongjiang Haerbin 150036, China;
2Heilongjiang Adverse Drug Reaction Monitoring Center, Heilongjiang Haerbin 150076, China

Received:2014-03-31 Revised:2016-02-03 Online:2014-10-08 Published:2016-03-02

Abstract

Abstract: ObjectiveTo explore the intervention measures of the adverse drug reaction(ADR) monitoring in agricultural reclamation area of Heilongjiang province. MethodsOn the basis of literature research, a questionnaire survey on 2010~2012 ADR monitoring of the agricultural reclamation area medical institutions was conducted. ResultsThere were some issues in the ADR management system, medical staff training and the medical institutions, and ADR monitoring department of construction. ConclusionTo enhance the effective monitoring of the ADR in the agricultural reclamation area, the ADR monitoring management departments should be improved, the ADR monitoring system construction of the medical institutions should be given a guarantee, propaganda and training methods of adverse drug reactions should be innovated.

Key words: agricultural reclamation area, adverse drug reaction, investigation

CLC Number:

R994.11

CHEN Hao-qun, XIA Hong-bo, ZHAO Shi-dan, HU Chen-xia, JIANG Zhi-yuan. Investigation on the Current Situation of Adverse Drug Reaction Monitoring in Agricultural Reclamation of Heilongjiang Province[J]. Chinese Journal of Pharmacovigilance, 2014, 11(10): 621-623.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[10]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[11]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[12]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[13]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.
[14]	LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue. Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
[15]	TAI Jun, YU Miao, ZHANG Lin, LEI Yi, LIU Junting, LI Tao, HUANG Guimin, CHENG Yijing, NIE Xiaolu, WANG Qing. Active monitoring of adverse reactions related to haemocoagulase agkistrodon for injection in children [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1011-1016.

Investigation on the Current Situation of Adverse Drug Reaction Monitoring in Agricultural Reclamation of Heilongjiang Province

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics